?? JSS, a Genesis Drug Discovery & Development (GD3) company, was deeply honored to receive recognition for more than 20 years of affiliation and active participation within the Association for the Advancement of Clinical Research in Colombia (AVANZAR). This award acknowledges JSS’s commitment, dedication, and excellence in the area of clinical research and contributions to the growth and development of #ClinicalResearch in Colombia and Latin America (LATAM) as a whole. ?? To speak with one of our experts and learn more about our capabilities and the benefits of conducting clinical trials in the LATAM region, click the following link https://lnkd.in/eRPXDeQz
Venenum BioDesign, LLC的动态
最相关的动态
-
Very much benefited from the information provided in the webinar. Although the cost penalty per day has seemingly gone down it can still have significant financial impact should the length go weeks or month without resolution. At Ubuntu Research we work with our clients to directly increase operating efficiency and reduce cost. By leveraging our unique approach, we trim development timelines from IND to BLA by up to 20%, which directly translates to enhanced eNPVs and reduced financing burdens. https://lnkd.in/eky3cw4S
New insights on the financial impact of delays in drug development have emerged! Join Ken Getz on Tuesday, September 10, 2024, at 1:00 p.m. Eastern Time (US & Canada) for a discussion on the latest findings by the Tufts Center for the Study of Drug Development. Learn about the updated measures of the financial value of a delay day in clinical research and its implications for stakeholders in drug development. REGISTER FOR FREE to gain valuable insights: https://lnkd.in/gjj23-vb Erik Yorke, Marina Filshtinsky, Deborah Borfitz, Allison Proffitt, ClinEco #SCOPEsummit #clinicalresearch
要查看或添加评论,请登录
-
-
?? Mark your calendars! The BMCS 4th Synthesis in Drug Discovery and Development 2024 is just around the corner. ?? June 4-5, 2024 ?? Virtual meeting Do not miss out this virtual symposium exploring the vital role of synthesis in drug discovery and development! Registration deadline: June 3rd, 2024 ?? https://lnkd.in/ebTH8NiX #BMCS #SDDD24 #DrugDiscovery #VirtualEvent
要查看或添加评论,请登录
-
-
Announcing the Illuminate Hypersomnia Adjunct Scientific Meeting happening February 13, 2025, from 12:00 – 2:00 p.m. EST. This virtual scientific session features leading global experts in the idiopathic hypersomnia (IH) field and aims to address critical challenges in drug development for IH. The agenda focuses on priorities identified by the IH patient community through the groundbreaking Illuminate Hypersomnia Externally Led Patient-Focused Drug Development meeting and survey. Learn more and register for the meeting at https://lnkd.in/ezvDE-vr. #IHPFDD #IlluminateIH #idiopathichypersomnia #livingwithIH #livingwithidiopathichypersomnia #idiopathichypersomnolence #PFDD #patientfocused #sleepconsortium #thisisIH
要查看或添加评论,请登录
-
-
Innovative approaches to clinical trials to improve the efficiency of drug development is the way forward. Some of the focuses in the pipeline include:- 1) point-of-care or pragmatic trials; 2) Bayesian analyses; and 3) trials using selective safety data collection.
Today, we launched the CDER Center for Clinical Trial Innovation (C3TI). C3TI’s mission is to promote CDER clinical trial innovation activities through enhanced communication and collaboration, both internally within CDER and externally:?https://lnkd.in/eKRvHYju C3TI will be a central hub within CDER that supports innovative approaches to clinical trials that are designed to improve the efficiency of drug development.?
要查看或添加评论,请登录
-
-
? Comparing the US & Europe Clinical Trial Landscapes ? Ahead of next week's COG New England, I sat down with Gary Quashie, of OPIS to discuss the challenges faced by #biopharma trial sponsors, as well as drawing comparisons from the European environment for #clinicaltrials. Key highlights from our discussion included: ?? Patient-centric trials have shown faster enrolment and initiation, emphasising the importance of including #patientadvocacy groups and CROs early in #protocoldevelopment ?? The US remains the top location for #clinicalresearch due to the FDA's robust framework, NIH support, renowned medical institutes, and a large, diverse patient population ?? The number of US trials are declining, China has seen a steady increase in recent years, though political impact is yet to be seen ?? Europe can be faster and more cost-effective for running studies, with strong Key Opinion Leader advocates and the streamlined European Clinical Trials Information System (#CTIS) regulatory process ?? Sponsors should partner with experienced CROs, leverage patient diversity plans, carefully assess #sitefeasibility, and embrace #patientcentric approaches and emerging technologies to navigate the evolving clinical trials landscape Read in full below ?? & meet Gary at COG New England next week!
要查看或添加评论,请登录
-
The University of Florida, Clinical & Translational Science Institute (CTSI) Investigational Drug Service faced significant operational challenges due to manual, paper-based processes. By adopting Vestigo?, they achieved remarkable efficiency and compliance improvements. Key achievements: ? 51.7% increase in protocol count ? 43% boost in revenue ? Improved staff efficiency and compliance Learn more about their journey and the measurable impact of Vestigo? in this success story: https://hubs.ly/Q032WKQ70 #ClinicalResearch #OperationalEfficiency #Innovation #Vestigo #Healthcare
要查看或添加评论,请登录
-
?? Missed the new ENETS-NANETS-Webinar: Highlights of PRRT and drug development abstracts? Now you can watch the video recording from the most prominent NEN experts from Europe and USA on clinical trials updates related to GEP NETs and #pheochromocytomas/#paragangliomas. ? Watch here: https://lnkd.in/dbDUuedg #LetsTalkAboutNETs #NeuroendocrineCancer?
要查看或添加评论,请登录
-
-
Assessing the likelihood of the success of a new pharmaceutical treatment requires context. Learn more about one way to look at that contextual information at the link below.
Managing Principals Jee-Yeon Lehmann and Stephen Fink interviewed academic affiliate Michael Kinch, creator of the Clinical Drug Experience Knowledgebase (CDEK), which can be used to assess trends and risks in the drug development process.
要查看或添加评论,请登录
#CRO #ClinicalTrials #RealWorldEvidence #Biotechnology #Pharmaceuticals #LifeSciences #GD3services